IMIBIC Mass Spectrometry and Molecular Imaging Unit (IMSMI)
IMIBIC Mass Spectrometry and Molecular Imaging Unit (IMSMI) provides highly specialised support in the latest mass spectrometry techniques available to those researchers and users who require it. This Unit is specialised in offering services in three of the major omics such as Proteomics, Lipidomics and Metabolomics. In addition, it is particularly specialised in Molecular Imaging (MS-Imaging).
The IMSMI Unit provides researchers with state-of-the-art technologies in the field and offers its services to IMIBIC research groups as well as to the University of Cordoba, Reina Sofia University Hospital, other universities, hospitals and private sector companies.
This Unit has four main lines of work:
- i) Clinical Proteomics line, consisting of a high-performance liquid chromatograph Evosep-One coupled to mass spectrometry (LC-MS/MS). It provides researchers and users with access to quantitative clinical proteomics analysis in liquid and without labelling (DDA, DIA-PASEF and PRM-PASEF). The studies that can be developed in this line range from small pilot experiments or small populations to large experiments with hundreds of samples and requiring superior speed and quality.
- ii) Lipidomics line, consisting of a liquid chromatograph coupled to mass spectrometry (LC-MS/MS). It provides a service for the identification and quantification of lipid species in samples in a targeted or untargeted manner at high resolution.
- iii) Metabolomics line, consisting of a liquid chromatograph coupled to mass spectrometry (LC-MS/MS). It offers a service for the identification and quantification of metabolites in samples in a targeted or untargeted manner at high resolution.
- iv) Molecular Imaging (MS-Imaging), which provides researchers and users with spatial information on metabolites, lipids, proteins/peptides directly from tissues and biopsies.
The IMSMI Unit provides individualised, fit-for-purpose support to its users, including project planning/experimental design, sample preparation, mass spectrometry analysis and basic and advanced data analysis, including the latest advances available in its area of expertise.
Equipment and Facilities
- Q-TOF mass spectrometer, TIMSTOF-Pro (Bruker) (Last update: 2021)
- Q-TOF mass spectrometer, Triple TOF 5600+ (Sciex) (Last update: 2014)
- Triple quadrupole mass spectrometer, XevoTQS (Waters) (Last update: 2014)
- MALDI-TOF/TOF Mass spectrometer, 5800 (Sciex) (Last update: 2014)
- EVOSEP-ONE (Evosep) (Last update: 2021)
- ELUTE UHPLC (Bruker) (Last update: 2021)
- nanoHPLC: Eksigent LC400 (Sciex) (Last update: 2014)
- nanoUPLC: nanoAcquity M-Class (Waters) (Last update: 2014)
- Sprayer: HTX M5 (HTX Technologies) (Last update: 2021)
- Sprayer: Sunchrom Suncollect (Sunchrom, Friedrichdorf, Germany) (Last update: 2014)
- Main programs (and programming languages) used for data analysis: Protein Pilot, Comet and X!Tandem, Proteowizard, TransProteomicsPipeline, MS-Fragger for protein identification; Peak View, Marker View, Skyline, DIANN, MS-Fragger for protein quantification and spectral library generation; Tissue View, MSiReader, Spectralanalysis, Cardinal, SCILS for Maldi Imaging MS. R, Python and Matlab for general analysis purposes (Last update: 2018 - 2021)
- PaSER: Parallel Search Engine in Real-time (Bruker) (Last update: 2021)
- Basic laboratory equipment for sample preparation (Last update: 2014)
- Identification and characterization of proteins by MALDI-TOF/TOF
- Identification and characterization of proteins by LC-MS/MS: DDA-PASEF
- Quantitative Proteomics:
- SRM (Selected Reaction Monitoring, QqQ)
- Clinical Proteomics analysis using Evosep-One
- Lipidomics and Metabolomics: Identification, characterization and/or quantification of small molecules in a wide range of sample precedence.
- MALDI Imaging mass spectrometry (Proteomics/Lipidomics)
- Project supervision and collaboration
- Training in software used for data analysis
- Optimization of a MALDI-Imaging protocol for studying adipose tissue-associated disorders. Fernández-Vega A, Chicano-Gálvez E, Prentice BM, Anderson D, Priego-Capote F, López-Bascón MA, Calderón-Santiago M, Avendaño MS, Guzmán-Ruiz R, Tena-Sempere M, Fernández JA, Caprioli RM, Malagón MM, Talanta.2020 Nov 1;219:121184. doi: 10.1016/j.talanta.2020
- González-Fernández MJ, Fabrikov D, Ramos-Bueno RP, Guil-Guerrero JL, Ortea I.SWATH Differential Abundance Proteomics and Cellular Assays Show in Vitro Anticancer Activity of Arachidonic Acid-and Docosahexaenoic Acid-Based Monoacylglycerols in HT-29 Colorectal Cancer Cells. Nutrients 2019, 11, 2984
- López-Sánchez LM, Jiménez Izquierdo R, Peñarando J, Mena R, Guil-Luna S, Toledano M, Conde F, Villar C, Díaz C, Ortea I, De la Haba-Rodríguez JR, Aranda E, Rodríguez-Ariza A.SWATH-based proteomics reveals processes associated with immune evasion and metastasis in poor prognosis colorectal tumours. J Cell Mol Med.2019, 23, 8219-8232
- Michán C, Chicano-Gálvez E, Fuentes-Almagro CA, Alhama J. Redox and global interconnected proteome changes in mice exposed to complex environmental hazards surrounding Doñana National Park. Environ Pollut 2019, 252, 427-439
- Böhme K, Calo-Mata P, Barros-Velázquez J, Ortea I. Recent applications of omics-based technologies to main topics in food authentication. TrAC - Trends in Analytical Chemistry 2019, 110, 221-232.
- Böhme, K.; Calo-Mata, P.; Barros-Velázquez, J.; Ortea, I. Review of Recent DNA-Based Methods for Main Food-Authentication Topics. Journal of Agricultural and Food Chemistry 2019, 67, 3854-3864.
- Garrido-Rodríguez M, Ortea I, Calzado MA, Muñoz E, García V. SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. J Proteomics. 2019, 20;193:217-229.
- Ortea I, Ruiz-Sánchez I, Cañete R, Caballero-Villarraso J, Cañete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. J Proteomics 2018, 20;175:105-113.
- Fernández A, Bayón GF, Sierra MI, Ortea I, Bonilla F, Fraga M. Loss of 5hmC identifies a new type of aberrant DNA hypermethylation in glioma. Hum Mol Genet. 2018 Sep 1;27(17):3046-3059.
- Ortea I, González-Fernández MJ, Ramos-Bueno RP, Guil-Guerrero JL. Proteomics Study Reveals That Docosahexaenoic and Arachidonic Acids Exert Different in Vitro Anticancer Activities in Colorectal Cancer Cells. J Agric Food Chem. 2018 Jun 20;66(24):6003-6012
- Prado M, Ortea I, Vial S, Rivas J, Calo-Mata P, Barros-Velázquez J. Advanced DNA- and protein-based methods for the detection and investigation of food allergens. Crit Rev Food Sci Nutr. 2016 Nov 17;56(15):2511-2542.
- Ortea I, Rodriguez-Ariza A, Chicano E, Arenas MS, Jurado B. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J Proteomics. 2016 Apr 14;138:106-14.
- Ghedira J, Chicano-Gálvez E, Fernández-Cisnal R, Jebali J, Banni M, Chouba L, Boussetta H, López-Barea J, Alhama J. Using environmental proteomics to assess pollutant response of Carcinus maenas along the Tunisian coast. Sci Total Environ. 2016 Jan 15;541:109-118.
- Ortea I, Roschitzki B et al. Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. PLoS One. 2016 Apr 6;11(4):e0153140.
- Ortea I, O'Connor G, Maquet A. Review on Proteomics for food authentication. J Proteomics. 2016 Sep 16;147:212-22.
- Chicano-Gálvez E, Asensio E, Cañavate JP, Alhama J, López-Barea J. Proteomic analysis through larval development of Solea senegalensis flatfish. Proteomics. 2015 Dec;15(23-24):4105-19.
- Abril N, Chicano-Gálvez E, Michán C, Pueyo C, López-Barea J. iTRAQ analysis of hepatic proteins in free-living Mus spretus mice to assess the contamination status of areas surrounding Doñana National Park (SW Spain). Sci Total Environ. 2015 Aug 1;523:16-27.
- de Andrés MC, Pérez-Pampín E, Calaza M, Santaclara FJ, Ortea I, Gómez-Reino JJ, González A. Assessment of global DNA methylation in peripheral blood cell subpopulations of early rheumatoid arthritis before and after methotrexate. Arthritis Res Ther. 2015 Aug 29;17:233